August 1, 2015

1999: Harmful experiments on the most vulnerabe

1999: Experiments on the most vulnerable The research community has consistently demonstrated its disregard for individual patient-subjects’

Read More
1999: Harmful experiments on the most vulnerabe

October 7, 2012

America’s Healthcare Crisis–Part II–What Do We Get for $$$ ?

IV. What Do We Get for All That Money? According to the Kaiser Foundation:[1] The number of

Read More
America’s Healthcare Crisis–Part II–What Do We Get for $$$ ?

September 15, 2012

US Healthcare Third Leading Cause of Death_Barbara Starfield, MD

Is US Healthcare Really the best in the World? Starfield_JAMA_2000  The findings by Barbara Starfield, MD, of

Read More
US Healthcare Third Leading Cause of Death_Barbara Starfield, MD

August 20, 2012

Rx Drugs Recalled for Safety Issues from US market

FDA Drug Recall Due to Safety Issues  1980 – 2011   Drug Name:                                                                Approved                               Withdrawn   Methaqualone

Read More
Rx Drugs Recalled for Safety Issues from US market

February 26, 2007

Counter-Detailing Anti-drug Reps Coming to Educate Doctors

There is a misperception that because a drug is an FDA-approved prescription medicine, it's safe and effective.

Read More
Counter-Detailing Anti-drug Reps Coming to Educate Doctors

January 22, 2007

Role of Litigation in Defining Drug Risks_JAMA / BMJ

Below are excerpts from two timely articles that offer persuasive arguments backed by evidence demonstrating that litigation

Read More
Role of Litigation in Defining Drug Risks_JAMA / BMJ

October 26, 2006

AHRP Files Court Brief to Protect Children from Harmful Research

October 1, 2001 Text of AHRP Amicus Brief filed with the Maryland Court of Appeals in support

Read More
AHRP Files Court Brief to Protect Children from Harmful Research

October 26, 2006

FDA: Regulatory Protections for Children. Comments by Sharav, Noble, & Fishman for AHRP

FDA: regulatory protections for children. Comments submitted by Vera Hassner Sharav, John H. Noble, Jr., Ph.D and

Read More
FDA: Regulatory Protections for Children. Comments by Sharav, Noble, & Fishman for AHRP

October 26, 2006

Dissenting Opinion: Against waiving parental permission for research

Dissenting Opinion: Against Waiving Parental Permission for Research July 25, 2001 To: Mary Faith Marshall, Ph.D, Chairperson,

Read More
Dissenting Opinion: Against waiving parental permission for research

October 26, 2006

The Impact of the FDA Modernization Act on the Recruitment of Children for Research

THE IMPACT OF THE FDA MODERNIZATION ACT ON THE RECRUITMENT OF CHILDREN FOR RESEARCH Vera Hassner Sharav

Read More
The Impact of the FDA Modernization Act on the Recruitment of Children for Research

October 26, 2006

Protecting Human Subjects in Research: Are Current Safeguards Adequate?

Protecting Human Subjects in Research: Are Current Safeguards Adequate? AHRP Testimony submitted to Congressional Committee April 23,

Read More
Protecting Human Subjects in Research: Are Current Safeguards Adequate?

October 26, 2006

Sharav / Cassidy – OHRP Testimony, 4/01

Testimony Submitted to the  Office of Human Research Protection (OHRP) by Vera Hassner Sharav and  Marie M.

Read More
Sharav / Cassidy – OHRP Testimony, 4/01

October 26, 2006

Drug Warnings: Are They Effective? USA Today

Drug Warnings: Are They Effective? USA Today Tue, 26 Apr 2005 How effective are drug warnings? USA

Read More
Drug Warnings: Are They Effective? USA Today

October 26, 2006

Merck / Johnson & Johnson/ Lilly-Zyprexa: $690 Million settlement / a Flowering of Diabetes Drugs

Merck / Johnson & Johnson/ Lilly-Zyprexa: $690 Million settlement / a Flowering of Diabetes Drugs Fri, 10

Read More
Merck / Johnson & Johnson/ Lilly-Zyprexa: $690 Million settlement / a Flowering of Diabetes Drugs